|
摘要：
|
|
摘要：目的 探讨经导管动脉载药微球栓塞与经导管动脉化疗栓塞治疗结直肠癌肝内转移的疗效。方法
选取2017年2月至2019年2月于简阳市人民医院进行治疗的70例结直肠癌肝内转移患者为研究对象，采
用随机数表法分为观察组（36例）和对照组（34例），对照组患者采用经导管动脉化疗栓塞，观察组
患者采用经导管动脉载药微球栓塞。比较两组患者治疗的总有效率、血清血管内皮生长因子（vascular
endothelial growth factor，VEGF）、癌胚抗原（carcinoembryonic antigen，CEA）、生存率及并发症。
结果 治疗后，观察组总有效率为77.78%（28/36），显著高于对照组的52.94%（18/34），差异有统计
学意义（χ 2 = 4.787，P = 0.029）。观察组患者治疗前后VEGF分别为（306.27 ± 80.71）ng/L、（224.15 ±
61.58）ng/L，CEA分别为（19.35 ± 5.42）μg/L、（12.06 ± 3.24）μg/L；对照组患者治疗前后VEGF分别为
（307.14 ± 81.72）ng/L、（269.37 ± 68.42）ng/L，CEA分别为（19.84 ± 5.53）μg/L、（16.51 ± 4.36）μg/L，
治疗前两组患者血清VEGF和CEA水平差异无统计学意义（P ＞ 0.05）；治疗后，两组患者血清VEGF、
CEA水平均较治疗前显著降低，且观察组显著低于对照组，差异均有统计学意义（P ＜ 0.05）。观
察组患者1年生存率[100.00%（36/36）vs 73.53%（25/34）]和2年生存率[83.33%（30/36）vs 58.82%
（20/34）]均显著高于对照组，差异有统计学意义（χ 2 值分别为10.935、5.147，P值分别为0.001、
0.023）。观察组和对照组不良反应发生率分别30.56%（11/36）、64.76%（21/34），差异有统计学意
义（χ 2 = 6.863，P = 0.009）。结论 经导管动脉载药微球栓塞治疗结直肠癌肝内转移效果显著，可有
效改善患者生存状况，不良反应少，值得推广应用。
|
|
Abstract: Objective To investigate the long-term efficacy of drug-eluting beads transcatheter arterial
chemoembolization and transcatheter arterial chemoembolization on colorectal cancer with intrahepatic
metastasis. Methods Total of 70 colorectal cancer patients with intrahepatic metastasis treated in Jianyang
People’s Hospital from February 2017 to February 2019 were selected and divided into observation group
(36 cases) and control group (34 cases) according to random number table method. Patients in control group
were treated with transcatheter arterial chemoembolization and patients in observation group were treated
with drug-eluting beads transcatheter arterial chemoembolization. The clinical efficacy, serum levels of
vascular endothelial growth factor (VEGF), cancer embryo antigen (CEA), survival rate and complications
were compared between the two groups. Results After treatment, the total efficacy rates of patients in
observation group and control group were 77.78% (28/36) and 52.94% (18/34), respectively. The difference
was statistically significant (χ 2 = 4.787，P = 0.029). VEGF levels of patients in observation group were
(306.27 ± 80.71) ng/L and (224.15 ± 61.58) ng/L before and after treatment, respectively. CEA levels of
patients in observation group were (19.35 ± 5.42) μg/L and (12.06 ± 3.24) μg/L before and after treatment,
respectively. VEGF levels of patients in control group were (307.14 ± 81.72) ng/L and (269.37 ± 68.42) ng/L
before and after treatment, respectively. CEA levels of patients in control group were (19.84 ± 5.53) μg/L and
(16.51 ± 4.36) μg/L before and after treatment, respectively. There were no significant differences in serum
levels of VEGF and CEA between the two groups before treatment (P ＞ 0.05). After treatment, the serum
VEGF and CEA levels of patients in two groups were significantly lower than those before treatment, which
were significantly lower in observation group than those in control group, the differences were statistically
significant (all P ＜ 0.05). The 1-year [100.00% (36/36) vs 73.53% (25/34)] and 2-year [83.33% (30/36) vs
58.82% (20/34)] survival rates of patients in observation group were significantly higher than those in control
group (χ 2 = 10.935, 5.147; P = 0.001, 0.023). The complication incidence of patients in observation group
and control group were 30.56% (11/36) and 64.76% (21/34), respectively. The difference was statistically
significant (χ 2 = 6.863, P = 0.009). Conclusions The efficacy of drug-eluting beads transcatheter arterial
chemoembolization on patients with metastasis is significant, which can effectively improve the survival
situation of the patients and with less adverse reactions. It is worthy of promotion and application.
|
|
基金项目：
|
|
|
|
作者简介：
|
|
|
|
参考文献：
|
|
|
|
服务与反馈：
|
|
【文章下载】【加入收藏】
|
|
|
|